Trial Profile
A Phase I Study of Monotherapy Dalotuzumab and Ridaforolimus-Dalotuzumab Combination Treatment in Pediatric Patients With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Dalotuzumab (Primary) ; Ridaforolimus (Primary)
- Indications CNS cancer; Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 10 May 2016 Results published in the European Journal of Cancer
- 03 Sep 2013 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
- 10 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.